Citius Pharmaceuticals (CTXR) will participate in two New York City investor conferences, with Chairman and CEO Leonard Mazur presenting and hosting investor meetings. The Maxim Growth Summit runs October 12–14, 2026; the ThinkEquity Conference is October 15, with a presentation scheduled for 3:00–3:30 p.m. ET, subject to change. Mazur will discuss recent developments, including ongoing LYMPHIR commercialization by majority-owned Citius Oncology (CTOR).

Citius Pharma CEO Leonard Mazur is scheduled to present Sept. 9 and 15 in New York, with one-on-one meetings and webcasts listed for both events; times may change.

Click to view the official SEC document.

Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Q3 Results as LYMPHIR Demand Builds

Click to view the official SEC document.

Citius Oncology (Nasdaq: CTOR) reported fiscal Q3 2026 results highlighted by initial LYMPHIR® commercialization. Revenue reached $1.5 million for the quarter and $7.1 million for the nine months ended June 30, 2026, versus no revenue a year earlier, generating gross profit of $1.0 million and $5.5 million, respectively.Institutional demand for LYMPHIR continued to build, with vial orders from prescribing centers up 31% sequentially (926 vs. 708) and 44 institutions having ordered since launch. The company reported near-universal payer coverage and expanded its commercial and medical affairs field force to 29 professionals. Cash and equivalents totaled $16.6 million, supported by $9.7 million in warrant exercises and funding of $10.0 million from the first tranche of a $25.0 million term loan. CTOR recorded a Q3 net loss of $8.9 million and a nine‑month net loss of $41.1 million, driven largely by commercial build‑out and a one‑time $19.7 million CMO contract cancellation charge.

Citius Pharmaceuticals (Nasdaq: CTXR) reported fiscal Q3 2026 results, highlighting initial commercial traction for LYMPHIR, launched by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR). For the three months ended June 30, 2026, Citius recorded $1.5 million in revenue and gross profit of $1.0 million, a ~67% gross margin. Nine-month revenue reached $7.1 million with a ~77% gross margin. Cash and cash equivalents were $17.0 million at June 30, 2026.LYMPHIR availability expanded to 44 institutions, institutional vial orders rose 31%, and new ordering institutions increased 80%. Citius Oncology completed nationwide deployment of 29 commercial and medical affairs professionals. Citius reported a Q3 2026 net loss applicable to common stockholders of $8.9 million and a nine‑month net loss of $38.3 million.

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors...

Citius Oncology (Nasdaq: CTOR)/b) announced that its Board of Directors has appointed , as an additional independent director, effective August 10, 2026, following a unanimous Board vote. His appointment increases the Board to nine members.According to Citius Oncology, Dr. Peri brings about three decades of leadership experience across higher education, financial services, law, and corporate governance, including roles as President of Manor College, former Vice President and General Counsel of Neumann University, and lead advisory board director of First State Bank. The company highlighted his background in strategic planning, fundraising, real estate, and legal and regulatory oversight, and stated that the Board has determined he qualifies as an independent director under applicable Nasdaq listing standards.

Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL).

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter. Initial cutaneous T-cell lymphoma market for LYMPHIR currently exceeds $400 million. CRANFORD, N.J., Aug. 5, 2026/ PRNewswire/-- Citius Oncology, Inc., an oncology‑ focused biopharmaceutical company and majority‑ owned subsidiary of Citius Pharmaceuticals, Inc., today provided an...

Citius Oncology (Nasdaq: CTOR), majority-owned by Citius Pharma (Nasdaq: CTXR), reported continued U.S. launch progress for LYMPHIR (denileukin diftitox-cxdl) for relapsed or refractory Stage I–III CTCL. The company has added 21 field-based commercial professionals and eight medical science liaisons, with nationwide deployment expected by August 2026.According to Citius Oncology, the May 2026 financing enabled this expansion, executed with exclusive commercialization partner EVERSANA, which also supplies integrated operational services. Management cites near 100% payer coverage, expanding ordering accounts across academic and community centers, and use of a proprietary AI-driven commercial intelligence platform. LYMPHIR, FDA-approved and launched in December 2025, addresses an estimated initial CTCL market exceeding $400 million.

Click to view the official SEC document.

LYMPHIR plus pembrolizumab showed 24% response and 21.1‑month duration in relapsed gynecologic cancers; data will be presented May 30 at ASCO 2026.

Click to view the official SEC document.

Citius Oncology (Nasdaq: CTOR) reported fiscal Q2 2026 results and a business update. LYMPHIR® generated $1.7 million in quarterly and $5.6 million in first-half 2026 net revenue at ~80% gross margins. About 83% of target accounts have LYMPHIR on formulary or in review, with near 100% commercial payer coverage and no reimbursement denials.The company held $2.6 million in cash at March 31, 2026, then secured up to $36.5 million in combined debt and equity in May. A one-time $19.7 million CMO contract cancellation drove G&A higher and contributed to a $26.6 million quarterly net loss.

Citius Pharmaceuticals (Nasdaq: CTXR) reported fiscal Q2 2026 results and a business update for majority-owned Citius Oncology (Nasdaq: CTOR). LYMPHIR generated $1.7M Q2 and $5.6M H1 2026 net revenue at ~80% gross margin, with payer coverage near 100% and 83% of target accounts on or in formulary review.Citius Pharma held $4.6M cash on March 31, 2026, then raised $5M via a registered direct offering. Citius Oncology arranged up to $36.5M in combined warrant and debt financing. Management expects combined funds to support operations through November 2026. Net loss to common stockholders was $21.2M in Q2 2026, including a $19.7M one-time CMO contract cancellation charge.The company highlighted initial LYMPHIR shipments to Europe via Uniphar, near-term completion of the U.S. commercial field force, and positive preliminary topline Phase 1 data from two investigator-initiated LYMPHIR combination studies. Engagement with the FDA continues for Mino-Lok and Halo-Lido.

Catch runners before the crowd AND track dilution on every stock. Share count changes, float risk, offering activity. $7/day. 100% money back. Battle-tested through every market cycle for 25+ years.

Through Named Patient Programs in specific markets, LYMPHIR gives eligible patients outside the U.S. access where approved alternatives may be limited.

Citius Pharmaceuticals has successfully closed a $5 million registered direct offering under Nasdaq rules, aimed at supporting the launch of its critical care product LYMPHIR.